Ordering
Available Variants25 mg
CHA.77936-25mg
Price
€198.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.77936-25mg | €198.40 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C13H11ClN2O2 |
|---|---|
| CAS Number | 1161205-04-4 |
| Molecular Weight | 262.69 |
| NACRES | NA.77 |
| PubChem Substance ID | 329825444 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD16618402 |
| Assay | ≥98% (HPLC) |
| Form | film |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302,H319 |
| pcodes | P264 - P280 - P301 + P312 - P305 + P351 + P338 - P337 + P313 - P501 |
| Hazard Classifications | Acute Tox. 4 Oral - Eye Irrit. 2 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
VU0361737, also known by its CAS number 1161205-04-4, is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor 4. This compound has been shown to exhibit high affinity for the target receptor, with a demonstrated ability to enhance glutamate-mediated receptor activation. In preclinical studies, VU0361737 has been investigated for its potential therapeutic applications, including the treatment of neurological and psychiatric disorders. The mechanism of action of VU0361737 involves the modulation of glutamatergic neurotransmission, which plays a critical role in various physiological and pathological processes. Further research is needed to fully elucidate the pharmacological profile and potential clinical utility of VU0361737, but initial findings suggest that this compound may represent a promising lead for the development of novel therapeutic agents. Its pharmacological properties make it an interesting candidate for further investigation.
